Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam

NCT05067790 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05067790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05067790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 21, 2022
Completion date
September 24, 2027
Enrollment
45 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy